GIST registry;Klinický registr GIST

Klinicka Onkologie

Volumn 25, Issue 2, 2012, Pages 135-138

  Jurečková, Andrea ^a   Kocakova I ^a   Vyzula, R ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

CANCER REGISTRY; GASTROINTESTINAL STROMAL TUMOR; SHORT SURVEY;

CZECH REPUBLIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; REGISTRIES;

EID: 84860519319     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Demetri GD, Benjamin R, Blanke CD et al. NCCN Task Force Report : Optimal management of patients with gastrointestinal stromal tumor (GIST). Expansion and Update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw 2004; 2: S1-S26.
2. Demetri G, van Oosterom A, Garrett C et al. Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. Gastrointestinal Cancers Symposium 2006.
3. Casali PG, Garrett CR, Blackstein ME et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006; 24(18 Suppl): 9513